Reports
Sale
Asia Pacific Biosimulation Market Size, Share, Analysis: By Product Type: Services, Software; By Application: Drug Development, Drug Discovery, Other Application; By Delivery Type: Subscription Model, Ownership Model; By End User: Biotechnology & Pharmaceutical Companies, Others; Regional Analysis; Supplier Landscape; 2024-2032
Asia Pacific Biosimulation Market Outlook
The global biosimulation market size was valued at USD 3.5 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising advancement in biosimulation technologies. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.
Key Takeaways
- The prevalence of at least one chronic disease among the adults and elderly population in India is estimated to be 41.73%. The rising burden of chronic disease fuels the need for effective drugs, thereby impacting market demand.
- In November 2023, Certara, Inc., introduced Simcyp™ Biopharmaceutics software which is designed to optimize the formulation and development of complex novel and generic small molecule medicines. The rising adoption of such technologically advanced biosimulation platforms in pharmaceutical and biotechnology companies is likely to elevate the Asia Pacific biosimulation market value.
- The market is positively influenced by increasing recognition of biosimulation technologies in improving clinical decisions and patient-specific therapies. In March 2024, a study on gastroesophageal cancer using the Cellworks Biosimulation Platform revealed superior overall survival (OS) and disease-free survival (DFS) predictions for the patients.
Asia Pacific Biosimulation Market Analysis
Biosimulation can be defined as a computational and mathematical modeling technique that is leveraged to simulate biological processes and systems. Biosimulation models can help predict the behavior of the drugs inside the human body, thereby reducing the time and cost associated with the drug development process. The rapid pharmaceutical expansion in the region is fuelling the demand for such simulation tools for accelerating drug development and is expected to significantly contribute to the Asia Pacific biosimulation market growth.
In Asia Pacific, healthcare demands are witnessing a surge due to an increasing prevalence of chronic diseases and the rising geriatric population in countries such as India and China. The prevalence of at least one chronic disease among the adults and elderly population in India is estimated to be 41.73%. This rising burden of chronic disease reflects the need to develop effective drugs faster. Since biosimulation can expedite the development of targeted therapy and personalized medicine, the market share is expected to grow in the forecast period.
One of the major Asia Pacific biosimulation market trends is the rise in launches of technologically advanced biosimulation software with enhanced capabilities and more accurate modeling. In November 2023, the global provider of biosimulation software and technology, Certara, Inc., introduced Simcyp™ Biopharmaceutics software which is designed to optimize the formulation and development of complex novel and generic small molecule medicines. It works by maximizing the safety and efficacy of therapies. The platform can help in predicting drug-drug interactions and drug performance in certain populations and can also replace costly clinical bioequivalence studies. The rising adoption of such biosimulation platforms in pharmaceutical and biotechnology companies in the region is likely to elevate the market value.
The Asia Pacific biosimulation market share is positively influenced by increasing recognition of biosimulation technologies in improving clinical decisions and patient-specific therapies. In March 2024, a study on gastroesophageal cancer using the Cellworks Biosimulation Platform (developed by Cellworks Group Inc.) revealed superior overall survival (OS) and disease-free survival (DFS) predictions for the patients. The study further highlighted the pivotal role of biosimulation in personalized therapy selection. Moreover, the increased application of biosimulation is expected to improve patient outcomes and lead to more cost-effective healthcare solutions. Consequently, this is likely to stimulate market demand in the coming years.
Asia Pacific Biosimulation Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Product Type | Services, Software |
| Application | Drug Development, Drug Discovery, Other Applications |
| Delivery Type | Subscription Model, Ownership Model |
| End User | Biotechnology & Pharmaceutical Companies, Research Institutes, Regulatory Authorities, Contract Research Organizations |
| Country | Japan, India, ASEAN, Australia, Others |
Asia Pacific Biosimulation Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- LeadInvent Technologies
- Certara Corporation
- Simulations Plus, Inc.
- Dassault Systèmes BIOVIA Corp.
- Insilico Medicine, Inc.
- Physiomics plc
- BioDuro LLC
- Accelrys, Inc.
- Genedata AG
- Rhenovia Pharma
- Biomedical Simulation, Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Application |
|
| Breakup by Delivery Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Asia Pacific Biosimulation Market Overview
3.1 Asia Pacific Biosimulation Market Historical Value (2017-2023)
3.2 Asia Pacific Biosimulation Market Forecast Value (2024-2032)
4 Asia Pacific Biosimulation Market Landscape*
4.1 Asia Pacific Biosimulation: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Asia Pacific Biosimulation: Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Application
5 Asia Pacific Biosimulation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Asia Pacific Biosimulation Market Segmentation (2017-2032)
6.1 Asia Pacific Biosimulation Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Services
6.1.3 Software
6.2 Asia Pacific Biosimulation Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Drug Development
6.2.3 Drug Discovery
6.2.4 Other Application
6.3 Asia Pacific Biosimulation Market (2017-2032) by Delivery Type
6.3.1 Market Overview
6.3.2 Subscription Model
6.3.3 Ownership Model
6.4 Asia Pacific Biosimulation Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Biotechnology & Pharmaceutical Companies
6.4.3 Research Institutes
6.4.4 Regulatory Authorities
6.4.5 Contract Research Organizations
6.5 Asia Pacific Biosimulation Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 Japan
6.5.3 India
6.5.4 ASEAN
6.5.5 Australia
6.5.6 Others
7 Japan Biosimulation Market (2017-2032)
7.1 Japan Biosimulation Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Services
7.1.3 Software
7.2 Japan Biosimulation Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Drug Development
7.2.3 Drug Discovery
7.2.4 Other Application
7.3 Japan Biosimulation Market (2017-2032) by Delivery Type
7.3.1 Market Overview
7.3.2 Subscription Model
7.3.3 Ownership Model
7.4 Japan Biosimulation Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Biotechnology & Pharmaceutical Companies
7.4.3 Research Institutes
7.4.4 Regulatory Authorities
7.4.5 Contract Research Organizations
8 India Biosimulation Market (2017-2032)
8.1 India Biosimulation Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Services
8.1.3 Software
8.2 India Biosimulation Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Drug Development
8.2.3 Drug Discovery
8.2.4 Other Application
8.3 India Biosimulation Market (2017-2032) by Delivery Type
8.3.1 Market Overview
8.3.2 Subscription Model
8.3.3 Ownership Model
8.4 India Biosimulation Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Biotechnology & Pharmaceutical Companies
8.4.3 Research Institutes
8.4.4 Regulatory Authorities
8.4.5 Contract Research Organizations
9 ASEAN Biosimulation Market (2017-2032)
9.1 ASEAN Biosimulation Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Services
9.1.3 Software
9.2 ASEAN Biosimulation Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Drug Development
9.2.3 Drug Discovery
9.2.4 Other Application
9.3 ASEAN Biosimulation Market (2017-2032) by Delivery Type
9.3.1 Market Overview
9.3.2 Subscription Model
9.3.3 Ownership Model
9.4 ASEAN Biosimulation Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Biotechnology & Pharmaceutical Companies
9.4.3 Research Institutes
9.4.4 Regulatory Authorities
9.4.5 Contract Research Organizations
10 Australia Biosimulation Market (2017-2032)
10.1 Australia Biosimulation Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Services
10.1.3 Software
10.2 Australia Biosimulation Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Drug Development
10.2.3 Drug Discovery
10.2.4 Other Application
10.3 Australia Biosimulation Market (2017-2032) by Delivery Type
10.3.1 Market Overview
10.3.2 Subscription Model
10.3.3 Ownership Model
10.4 Australia Biosimulation Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Biotechnology & Pharmaceutical Companies
10.4.3 Research Institutes
10.4.4 Regulatory Authorities
10.4.5 Contract Research Organizations
11 Regulatory Framework
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication Year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by Departments
13.7 Analysis by Recipient Organization
14 Funding and Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1 Market Share by Top 5 Companies
16.2 LeadInvent Technologies
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Certara Corporation
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Simulations Plus, Inc.
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Dassault Systèmes BIOVIA Corp.
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Insilico Medicine, Inc.
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Physiomics plc
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 BioDuro LLC
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Accelrys, Inc.
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Genedata AG
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Rhenovia Pharma
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
16.12 Biomedical Simulation, Inc.
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisitions
16.12.5 Certifications
17 Asia Pacific Biosimulation Market – Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Asia Pacific biosimulation market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 16.90% during the forecast period of 2024-2032 and is likely to reach a market value of USD 14.1 billion by 2032.
The rising advancement in biosimulation technologies is fuelling the demand for the market.
One of the significant trends in the market is the rise in launches of technologically advanced biosimulation software with enhanced capabilities. In November 2023 , Certara, Inc., introduced Simcyp™ Biopharmaceutics software which is designed to optimize the formulation and development of complex novel and generic small molecule medicines.
Based on the product type, the market is segmented into services and software.
By delivery type, the market is divided into the subscription model and ownership model.
End users of the market are biotechnology and pharmaceutical companies, research institutes, regulatory authorities, and contract research organizations.
Major applications of biosimulation include drug development, and drug discovery, among other applications.
The market segmentation by countries includes Japan, India, ASEAN, and Australia, among others.
The key players in the market are LeadInvent Technologies, Certara Corporation, Simulations Plus, Inc., Dassault Systèmes BIOVIA Corp., Insilico Medicine, Inc., Physiomics plc, BioDuro LLC, Accelrys, Inc., Genedata AG, Rhenovia Pharma, and Biomedical Simulation, Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER